Docket No.: 6056-257 (35926-147538)

AMENDMENT AND REPLY UNDER 37 C.F.R. § 1.111

In re: application of: Keith R. McRae
Application No.: 09/437,912

EXHIBIT B A copy of the pending claims

1. A pharmaceutical composition comprising a pharmaceutically acceptable carrier and a compound of the formula X_1 -His-Lys- X_2 wherein

X is any amino acid,

 X_1 is the segment His-Gly-His-Glu-Gln-Gln-His-Gly-Leu-Gly-His-Gly (SEQ ID NO:1), or an N-terminal truncation fragment thereof containing at least one amino acid, and X_2 is

- (i) zero amino acids, or
- (ii) the segment Leu-Asp-Asp-Leu-Glu-His-Gln-Gly-Gly-His-Val (SEQ ID NO:2), or a C-terminal truncation fragment thereof containing at least one amino acid, and wherein said compound optionally comprises an amino-terminal protecting group and optionally comprises a carboxy-terminal protecting group.
 - The composition of claim 1 wherein
 X₁ is from one to six amino acids in length, and
 X₂ is from zero to six amino acids in length.
- 3. The composition of claim 1 wherein X is selected from the group consisting of Ala, Leu, Ile, Val, Pro, Phe, Trp, Met, Ser, Thr, Tyr, Asn, Gln, Cys, and Gly.
 - 4. The composition of claim 3 wherein X is Asn, Phe or His.
 - 5. Cancelled
 - 6. Cancelled

35926-147538 DC\378367\3 Docket No.: 6056-257 (35926-147538)

In re: application of: Keith R. McRae

AMENDMENT AND REPLY UNDER 37 C.F.R. § 1.111

Application No.: 09/437,912

7. Cancelled

- 8. The composition of claim 1 wherein the compound has the amino acid sequence His-Gly-His-Glu-Gln-His-Gly-Leu-Gly-His-Gly-His-Lys-Phe-Lys-Leu-Asp-Asp-Asp-Leu-Glu-His-Gln-Gly-Gly-His-Val (SEQ ID NO:5).
- 9. The composition of claim 1 wherein the compound has the amino acid sequence Gly-His-Lys-Phe-Lys-Leu-Asp-Asp-Leu-Glu-His-Gln-Gly-Gly-His(SEQ ID NO:7).
 - 10. Cancelled
 - 11. Cancelled
 - 12. Cancelled
 - 13. Cancelled
 - 14. Cancelled
 - 15. Cancelled
- 16. A method of inhibiting angiogenesis comprising administering to a mammal an effective amount of a pharmaceutical composition comprising a pharmaceutically acceptable carrier and a compound of the formula X₁-His-Lys-X-Lys-X₂ wherein

X is any amino acid,

X₁ is from zero to twelve amino acids, and

X₂ is from zero to twelve amino acids,

Docket No.: 6056-257 (35926-147538) AMENDMENT AND REPLY UNDER 37 C.F.R. § 1.111 In re: application of: Keith R. McRae Application No.: 09/437,912

and wherein said compound optionally comprises an amino-terminal protecting group and optionally comprises a carboxy-terminal protecting group.

optionally comprises a carboxy-terminal protecting group.		
	17.	Cancelled
	18.	Cancelled
effecti	19. ve amo	A method of inhibiting angiogenesis comprising administering to a mammal an unt of a two-chain high molecular weight kininogen.
	20.	Cancelled
	21.	Cancelled
effecti	22. ve amo	A method of inhibiting angiogenesis comprising administering to a mammal an unt of a single-chain high molecular weight kininogen.
	23.	Cancelled
	24.	Cancelled
	25.	Cancelled
	26.	Cancelled
	27.	Cancelled
	28.	Cancelled

Docket No.: 6056-257 (35926-147538)

AMENDMENT AND REPLY UNDER 37 C.F.R. § 1.111

In re: application of: Keith R. McRae
Application No.: 09/437,912

29. Cancelled

30. A compound of the formula X₁-His-Lys-X-Lys-X₂ wherein X is any amino acid,

 X_1 is the segment His-Gly-His-Glu-Gln-His-Gly-Leu-Gly-His-Gly (SEQ ID NO:1), or N-terminal truncation fragment thereof containing at least one amino acid, and X_2 is

- (i) zero amino acids, or
- (ii) the segment Leu-Asp-Asp-Leu-Glu-His-Gln-Gly-Gly-His-Val (SEQ ID NO:2), or C-terminal truncation fragment thereof containing at least one amino acid, and wherein said compound optionally comprises an amino-terminal protecting group and optionally comprises a carboxy-terminal protecting group.
 - 31. The compound of claim 30 wherein X is Asn, Phe or His.
- 32. The compound of claim 30 having at least about 30% amino acid sequence homology to the amino acid sequence His-Gly-His-Glu-Gln-Gln-His-Gly-Leu-Gly-His-Gly-His-Lys-Phe-Lys-Leu-Asp-Asp-Asp-Leu-Glu-His-Gln-Gly-Gly-His-Val (SEQ ID NO:5).
- 33. The compound of claim 30 having the amino acid sequence Gly-His-Lys-Phe-Lys-Leu-Asp-Asp-Leu-Glu-His-Gln-Gly-Gly-His (SEQ ID NO:7).
- 34. A compound consisting essentially of the amino acid sequence Lys-His-Gly-His-Gly-His-Gly-Lys-His-Lys-Asn-Lys-Gly-Lys-Lys-Asn (SEQ ID NO:8).
- 35. A compound consisting essentially of the amino acid sequence His-Lys-Asn-Lys-Gly-Lys-Asn-Gly-Lys-His-Asn-Gly-Trp-Lys-Thr (SEQ ID NO:9).

Docket No.: 6056-257 (35926-147538)

AMENDMENT AND REPLY UNDER 37 C.F.R. § 1.111

In re: application of: Keith R. McRae Application No.: 09/437,912

36. The method of claim 16, whereinX₁ is from zero to six amino acids, andX₂ is from zero to six amino acids.

- 37. The method of claim 16, wherein X is selected from the group consisting of Ala, Leu, Ile, Val, Pro, Phe, Trp, Met, Ser, Thr, Tyr, Asn, Gln, Cys and Gly.
 - 38. The method of claim 37 wherein X is Asn, Phe, or His.
 - 39. The method of claim 16, wherein

 X_1 is

- (i) zero amino acids, or
- (ii) the segment His-Gly-His-Glu-Gln-Gln-His-Gly-Leu-Gly-His-Gly (SEQ ID NO:1), or an N-terminal truncation fragment thereof containing at least one amino acid, and

X₂ is

- (i) zero amino acids, or
- (ii) the segment Leu-Asp-Asp-Leu-Glu-His-Gln-Gly-Gly-His-Val (SEQ. ID NO:2), or a C-terminal truncation fragment thereof containing at least one amino acid.
 - 40. The method of claim 39 wherein X is Asn, Phe or His.
- 41. The method of claim 16, wherein the compound has at least 30% amino acid sequence homology to the amino acid sequence His-Gly-His-Glu-Gln-Gln-His-Gly-Leu-Gly-His-Gly-His-Lys-Phe-Lys-Leu-Asp-Asp-Leu-Glu-His-Gln-Gly-Gly-His-Val (SEQ ID NO:5).


Docket No.: 6056-257 (35926-147538)

AMENDMENT AND REPLY UNDER 37 C.F.R. § 1.111

In re: application of: Keith R. McRae
Application No.: 09/437,912

42. The method of claim 16, wherein the compound has the amino acid sequence His-Gly-His-Glu-Gln-Gln-His-Gly-Leu-Gly-His-Lys-Phe-Lys-Leu-Asp-Asp-Asp-Leu-Glu-His-Gly-Gly-His-Val (SEQ ID NO:5).

- 43. The method of claim 16, wherein the compound has the amino acid sequence Gly-His-Lys-Phe-Lys-Leu-Asp-Asp-Asp-Leu-Glu-His-Gln-Gly-Gly-His (SEQ ID NO:7).
 - The method of claim 16, whereinX₁ is
 - (i) zero amino acids, or
- (ii) the segment Gly-His-Lys-His-Lys-His-Gly-His-Gly-Lys (SEQ ID NO:3) or an N-terminal truncation fragment thereof containing at least one amino acid, and X_2 is
 - (i) zero amino acids, or
- (ii) the segment Gly-Lys-Lys-Asn-Gly-Lys-His-Asn-Gly-Trp-Lys-Thr (SEQ ID NO:4) or a C-terminal truncation fragment thereof containing at least one amino acid.
 - 45. The method of claim 44 wherein X is Asn, Phe, or His.
- 46. The method of claim 44, wherein the compound has at least 30% amino acid sequence homology to the amino acid sequence Gly-His-Lys-His-Lys-His-Gly-His-Gly-Lys-His-Lys-Asn-Lys-Gly-Lys-Lys-Asn-Gly-Lys-His-Asn-Gly-Trp-Lys-Thr (SEQ ID NO:6).
- 47. The method of claim 44, wherein the compound has the amino acid sequence Gly-His-Lys-His-Lys-His-Gly-His-Gly-Lys-His-Lys-Asn-Lys-Gly-Lys-Lys-Asn-Gly-Lys-His-Asn-Gly-Trp-Lys-Thr (SEQ ID NO:6).



48. The method of claim 44, wherein the compound has the amino acid sequence Lys-His-Gly-His-Gly-Lys-His-Lys-Asn-Lys-Gly-Lys-Lys-Asn (SEQ ID NO:8).

49. The method of claim 44, wherein the compound has the amino acid sequence His-Lys-Asn-Lys-Gly-Lys-Lys-Asn-Gly-Lys-His-Asn-Gly-Trp-Lys-Thr (SEQ ID NO:9).